About Zikani Therapeutics
Zikani Therapeutics is using its innovative chemistry technology platform to develop novel Ribosome Targeting Molecules. We are focused on developing and commercializing therapeutics for patients with limited treatment options.
At Zikani, we start with a rational approach to designing Ribosome Targeting Molecules (RTMs), that expands the structural diversity of these molecules. Our goal is to develop breakthrough RTMs that are orally delivered, safe and potent for the most difficult diseases.
MEET OUR TEAM
Sumit has over 20 years of pharmaceutical and biotechnology commercial operations, investment management and management consulting experience. Before joining Zikani, Sumit was the President and CFO of Progenity where he helped raise $125million in capital and transformed the company into a highly profitable genetic services lab with a novel drug delivery-based GI pipeline. Previously, Sumit was a healthcare and biotechnology Portfolio Manager at Adage Capital and an Associate Partner in McKinsey & Company’s healthcare practice. Sumit has an MBA with distinction from the Johnson School, Cornell University and a Bachelor of Technology with Honors in Chemical Engineering from the Indian Institute of Technology, Kharagpur.
President & CEO
Sumit Aggarwal has served as our President and CEO since March 2019 and was previously our Chief Financial and Chief Business Officer.
Prior to joining, he served as the Chief Scientific Officer at Translate Bio where he was responsible for overall scientific vision, strategic direction, and leadership of Research and Development. Tom has made significant contributions to the development and global approvals of a number of marketed products, including Replagal®, Vpriv®, Elaprase®, Firazyr® and Xiidra®. Tom has authored more than 40 scientific publications, book chapters, and patents. He holds undergraduate and graduate degrees from Cornell University and received his Ph.D. from the University of Alabama at Birmingham.
Chief Scientific Officer
Thomas McCauley is the Chief Scientific Officer at Zikani Therapeutics and has over 20 years of experience in preclinical and clinical discovery and development of biologic and small molecule drugs for indications in respiratory disease, cardiovascular disease, hematology, oncology, inflammation and ophthalmology.
Prior to joining, he held multiple roles at Discovery, Development, IP, and Business Development for out- and in-licensing at Cubist and Optimer Pharmaceuticals, and had worked on DIFICID® for C. difficile infections. He has extensive experience in Chemistry and Biology of Ribosome targeting molecules. He is an author of 100 peer-reviewed publications/book chapters and an inventor of more than 10 issued patents.
Vice President, Technology Development and Partnering
Yoshi Ichikawa, Ph.D., is the VP, Technology Development and Partnering at Zikani Therapeutics and has over 30 years of medicinal chemistry, molecular biology and drug development experience.
Prior to joining, Roger was the Senior Director of Medicinal Chemistry at Tetraphase Pharmaceuticals where he contributed to the discovery and development of four clinical compounds, including Eravacycline. As a medicinal chemist, Roger has extensive experience across multiple therapeutic areas, including oncology and metabolic disorders (Bayer Pharmaceuticals) and inflammation (Critical Therapeutics). Dr. Clark received his Ph.D. in Organic Chemistry from the University of Michigan and is a co-author of 15 publications in peer-reviewed scientific journals and a co-inventor on 10 issued patents.
Vice President, Chemistry
Roger Clark, Ph.D., is the Vice President of Chemistry at Zikani Therapeutics with 20 years of R&D experience spanning all phases of the discovery and pre-clinical development process.
Prior to Zikani, Joe was the Head of Biology at Tetraphase Therapeutics and supported NDA and MAA submissions for Xerava®. Prior to Tetraphase, Joe spent 10 years at AstraZeneca, in various roles supporting early development and IND submissions for a number of drugs currently in development. Joe received his undergraduate degree in Biology from the University of Delaware, his Ph.D. in Molecular Microbiology from the University of Rhode Island, and completed fellowships at Tufts Medical School and MIT.
Vice President, Early Development
Joe Newman, Ph.D., is the VP, of Early Development at Zikani Therapeutics. Joe has over 17 years of experience, supporting all stages of drug development from lead optimization to clinical development.
Jianmin made significant contributions to a number of programs in various development stages, most notably Baxdela®, Derazantinib, Miransertib, and Tivantinib. Jianmin received his Ph.D. in Organic Chemistry from Lanzhou University, China and is an author of more than 30 peer-reviewed publications and an inventor on 12 issued patents.